ÂÜÀòÂÒÂ×

Susan brings over 30 years of experience in regulatory affairs, with a focus on pain and CNS therapies Prior to joining Eliem, she most recently served as the Senior Vice President and Head of Regulatory Affairs at Braeburn Inc., where she was responsible for managing the regulatory team across all CMC, clinical, and non-clinical operations and promotional functions with a focus on its opioid use disorder (OUD) and pain pipeline. Previously, she managed global regulatory affairs at Teva Pharmaceuticals, Cephalon, Premier Research Group, and Wyeth Pharmaceuticals. Over the course of her career, Susan led the successful registration of Exalgo® (hydromorphone extended release) and Vantrela® ER (hydrocodone), the tentative approval for Brixadi™ (buprenorphine extended-release) as well as leading several successful FDA Advisory Committees. Susan holds a BS in Chemistry from Clarkson University and an MS in Chemistry from Lehigh University.